Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812053 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7561589 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8205042 | 0.82 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7352894 | 0.82 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7458617 | 0.82 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL10194861 | 0.82 | SLC6A2 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL522190 | 0.81 | SLC6A2 (0.43) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7560904 | 0.81 | SLC6A2 (0.58) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5971564 | 0.81 | CHRM1 (0.58) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4781131 | 0.81 | SLC18A3 (0.49) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| EP-1233968-A2 | TRANSITION METAL-CYCLOPENTADIENYL-TROPANE CONJUGATES | YALE UNIVERSITY (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020111486-A1 | Transition metal-cyclopentadienyl-tropane conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-15 | — | — | US | disclosed |
| WO-2001040239-A2 | TRANSITION METAL-CYCLOPENTADIENYL-TROPANE CONJUGATES | YALE UNIVERSITY (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0988263-A1 | PROCESS FOR THE PRODUCTION OF RADIOIODINATED NEURORECEPTOR AGENTS | Map Medical Technologies Oy (FI) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057909-A1 | PROCESS FOR THE PRODUCTION OF RADIOIODINATED NEURORECEPTOR AGENTS | MAP MEDICAL TECHNOLOGIES OY (FI) | 1998-12-23 | — | — | WO | disclosed |
| WO-1997012513-A1 | DOPAMINE TRANSPORTER KNOCKOUT MICE | DUKE UNIVERSITY (US) | 1997-04-10 | — | — | WO | disclosed |
| EP-0542903-A4 | COCAINE RECEPTOR BINDING LIGANDS | RES TRIANGLE INST (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0542903-A1 | COCAINE RECEPTOR BINDING LIGANDS. | RES TRIANGLE INST (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992002260-A1 | COCAINE RECEPTOR BINDING LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111486-A1 | Transition metal-cyclopentadienyl-tropane conjugates | SLC6A3, SLC18A2, SLC6A2 | SLC6A4 5/4885SLC6A3 1/4885SLC6A2 3/4885 |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | SLC6A4 554/4885SLC6A3 1034/4885SLC6A2 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.